Drug Trial Radar · NCT04083976
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
316
Actual
Start
Nov 20, 2019
Primary completion
Dec 4, 2023
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) alterations (mutations or gene fusions). It will also evaluate ORR in pediatric participants with advanced solid tumors and FGFR alterations.
Conditions
- Advanced Solid Tumor
Interventions
ErdafitinibDrug
Participants will receive erdafitinib oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Broad Panel and Pediatric Cohorts: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)Time frame: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 4 years
- Core Panel Cohort: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)Time frame: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 4 years
Locations
179 sites in 15 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona
Rocky Mountain Cancer Centers
Colorado Springs, Colorado
Memorial Cancer Institute
Hollywood, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Emory University
Atlanta, Georgia
Hawaii Cancer Care
‘Aiea, Hawaii
Maine Medical Center
Scarborough, Maine
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Hackensack University Medical Center
Hackensack, New Jersey
Mount Sinai
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Levine Cancer Institute, Carolinas HealthCare System
Charlotte, North Carolina
Oncology Hematology Care
Cincinnati, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Tennessee Oncology, PLLC
Chattanooga, Tennessee
Tennessee Oncology
Nashville, Tennessee
Texas Oncology Baylor Charles A Sammons Cancer Center
Dallas, Texas
Texas Oncology-Fort Worth Cancer Center
Fort Worth, Texas
MD Anderson
Houston, Texas
Oncology Consultants Texas
Houston, Texas
Texas Oncology Odessa-West Texas Cancer Center
Odessa, Texas
Texas Oncology San Antonio Northeast
San Antonio, Texas
NorthWest Medical Specialties, PLLC
Tacoma, Washington
Aurora Research Institute
Wauwatosa, Wisconsin
Instituto de Investigaciones Metabólicas
Buenos Aires, Argentina
Hospital Aleman
Buenos Aires, Argentina
Centro Oncológico Korben
Buenos Aires, Argentina
Instituto Fleni
Buenos Aires, Argentina
CEMIC Saavedra
Buenos Aires, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
Córdoba, Argentina
Hospital Italiano de La Plata
La Plata Lpl Lpl, Argentina
Instituto de Investigaciones Clinicas Mar del Plata
Mar del Plata, Argentina
Hospital Privado de Comunidad
Mar del Plata, Argentina
Hospital Universitario Austral
Pilar, Argentina
Sanatorio Britanico de Rosario
Rosario, Argentina
ARS Médica
San Salvador de Jujuy, Argentina
Flinders Centre for Innovation in Cancer
Adelaide, Australia
Showing 40 of 179 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.